Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

Jia Jia; Lili Mao; Jing Lin; Wenyu Li; Pei Yuan; Lei Guo; Jie Dai; Caili Li; Xue Bai; Zhongwu Li; Yu Chen; Jun Guo; Jianming Ying; Lu Si

doi:10.1007/s11684-023-1046-2

Front. Med. ›› 2024, Vol. 18 ›› Issue (3) : 565 -569. DOI: 10.1007/s11684-023-1046-2

LETTER TO FRONTIERS OF MEDICINE

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

Author information +

History +

PDF (949KB)

Cite this article

Download citation ▾

Jia Jia, Lili Mao, Jing Lin, Wenyu Li, Pei Yuan, Lei Guo, Jie Dai, Caili Li, Xue Bai, Zhongwu Li, Yu Chen, Jun Guo, Jianming Ying, Lu Si. Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy. Front. Med., 2024, 18(3): 565-569 DOI:10.1007/s11684-023-1046-2

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Jeong SH, Hyeong JH, Park EJ, Kim KJ, Kim KH. Human epidermal growth factor receptor 2 expression in extramammary Paget’s disease and mammary Paget’s disease. Australas J Dermatol 2022; 63(1): 115–118

[2]

Angelico G, Santoro A, Inzani F, Straccia P, Arciuolo D, Mulè A, Valente M, Spadola S, D’Alessandris N, Garganese G, Cianfrini F, Piermattei A, Scambia G, Zannoni GF. Hormonal environment and HER2 status in extra-mammary Paget’s disease (eMPD): a systematic literature review and meta-analysis with clinical considerations. Diagnostics (Basel) 2020; 10(12): 1040

[3]

Sekiguchi N, Kubota S, Noguchi T, Fukushima T, Kobayashi T, Kanda S, Koizumi T, Miyake T, Shirai T, Okuyama R. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget’s disease: four cases and a review. J Dermatol 2020; 47(11): 1276–1279

[4]	National Medical Products Administration. Disitamab vedotin: NMPA Approval notice. 2021, available from the website of NMPA

[5]	RemeGen. Disitamab vedotin: Chinese prescribing information. Yantai. 2021

[6]

Wang J, Liu Y, Zhang Q, Feng J, Fang J, Chen X, Han Y, Li Q, Zhang P, Yuan P, Ma F, Luo Y, Fan Y, Cai R, Chen S, Li Q, Li Y, Xu B. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies. J Clin Oncol 2021; 39(15 Suppl): 1022 (abstract no. 1022)

[7]

Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, Mao C, Fan Q, Bai Y, Ba Y, Jiang D, Yang F, Qi C, Li J, Wang X, Zhou J, Lu M, Cao Y, Yuan J, Liu D, Wang Z, Fang J, Shen L. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021; 24(4): 913–925

[8]

Zattarin E, Nichetti F, Ligorio F, Mazzeo L, Lobefaro R, Fucà G, Peverelli G, Vingiani A, Bianchi GV, Capri G, de Braud F, Vernieri C. Case Report: prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. Front Oncol 2022; 12: 925551

[9]	Shin DS, Sherry T, Kallen ME, Wong S, Drakaki A. Human epidermal growth factor receptor 2 (HER-2/neu)-directed therapy for rare metastatic epithelial tumors with HER-2 amplification. Case Rep Oncol 2016; 9(2): 298–304

[10]	Tokuchi K, Maeda T, Kitamura S, Yanagi T, Ujiie H. HER2-targeted antibody-drug conjugates display potent antitumor activities in preclinical extramammary Paget’s disease models: in vivo and immunohistochemical analyses. Cancers (Basel) 2022; 14(14): 3519